secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001558370-23-003776
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023
-----------------------------------------------------------------------------

- Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.
- Q4 revenue $7.8M, full-year $14.2M (down from $18.4M); net loss $64.9M for 2022 vs $75.7M in 2021.
- HB-200 Phase 2 data (with pembrolizumab) due 2Q2023; HB-300 trial open; HB-700 IND planned 1H2024.
- Roche collaboration: $10M milestone Feb 2023; potential milestones up to $930M plus royalties.
- Gilead HBV milestone $5M Jan 2023; HIV program IND expected 2023; HB-101 program discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/0001558370-23-003776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/hook-20230315x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer